The Centers for Medicare & Medicaid Services (CMS) has revealed its selection of 15 drugs for a new round of price negotiations under the Medicare program. This list includes high-profile medications such as Botox and Trulicity, marking the first time Part B drugs have been included in negotiations. The chosen drugs address a range of medical conditions, including cancer and diabetes, as the Trump administration emphasizes its commitment to lowering drug prices for Medicare recipients. Effective pricing agreements for these drugs are expected to be implemented in the coming years.